{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T23:46:58Z","timestamp":1793317618644,"version":"4.5.0"},"reference-count":87,"publisher":"MDPI AG","issue":"8","license":[{"start":{"date-parts":[[2022,8,14]],"date-time":"2022-08-14T00:00:00Z","timestamp":1660435200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceuticals"],"abstract":"<jats:p>Radiolabeled FAPI (fibroblast activation protein inhibitors) recently gained attention as widely applicable imaging and potential therapeutic compounds targeting CAF (cancer-associated fibroblasts) or DAF (disease-associated fibroblasts in benign disorders). Moreover, the use of FAPI has distinct advantages compared to FDG (e.g., increased sensitivity in regions with high glucose metabolism, no need for fasting, and rapid imaging). In this study, we wanted to evaluate the radiochemical synthesis and the clinical properties of the new CAF-targeting tracer [68Ga]Ga-DATA5m.SA.FAPi. The compound consists of a (radio)chemically easy to use hybrid chelate DATA.SA, which can be labeled at low temperatures, making it an interesting molecule for \u2018instant kit-type\u2019 labeling, and a squaric acid moiety that provides distinct advantages for synthesis and radiolabeling. Our work demonstrates that automatic synthesis of the FAP inhibitor [68Ga]Ga-DATA5m.SA.FAPi is feasible and reproducible, providing convenient access to this new hybrid chelator-based tracer. Our studies demonstrated the diagnostic usability of [68Ga]Ga-DATA5m.SA.FAPi for the unambiguous detection of cancer-associated fibroblasts of various carcinomas and their metastases (NSCLC, liposarcoma, parotid tumors, prostate cancer, and pancreas adenocarcinoma), while physiological uptake in brain, liver, intestine, bone, and lungs was very low.<\/jats:p>","DOI":"10.3390\/ph15081000","type":"journal-article","created":{"date-parts":[[2022,8,15]],"date-time":"2022-08-15T03:33:20Z","timestamp":1660534400000},"page":"1000","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["From Automated Synthesis to In Vivo Application in Multiple Types of Cancer\u2014Clinical Results with [68Ga]Ga-DATA5m.SA.FAPi"],"prefix":"10.3390","volume":"15","author":[{"given":"Lukas","family":"Greifenstein","sequence":"first","affiliation":[{"name":"CURANOSTICUM Wiesbaden-Frankfurt, Center for Advanced Radiomolecular Precision Oncology, 65191 Wiesbaden, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carsten S.","family":"Kramer","sequence":"additional","affiliation":[{"name":"CURANOSTICUM Wiesbaden-Frankfurt, Center for Advanced Radiomolecular Precision Oncology, 65191 Wiesbaden, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0447-1355","authenticated-orcid":false,"given":"Euy Sung","family":"Moon","sequence":"additional","affiliation":[{"name":"Department of Chemistry\u2013TRIGA, Institute of Nuclear Chemistry, Johannes Gutenberg University, 55128 Mainz, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"R\u00f6sch","sequence":"additional","affiliation":[{"name":"Department of Chemistry\u2013TRIGA, Institute of Nuclear Chemistry, Johannes Gutenberg University, 55128 Mainz, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andre","family":"Klega","sequence":"additional","affiliation":[{"name":"CURANOSTICUM Wiesbaden-Frankfurt, Center for Advanced Radiomolecular Precision Oncology, 65191 Wiesbaden, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Landvogt","sequence":"additional","affiliation":[{"name":"CURANOSTICUM Wiesbaden-Frankfurt, Center for Advanced Radiomolecular Precision Oncology, 65191 Wiesbaden, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corinna","family":"M\u00fcller","sequence":"additional","affiliation":[{"name":"CURANOSTICUM Wiesbaden-Frankfurt, Center for Advanced Radiomolecular Precision Oncology, 65191 Wiesbaden, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1723-0075","authenticated-orcid":false,"given":"Richard P.","family":"Baum","sequence":"additional","affiliation":[{"name":"CURANOSTICUM Wiesbaden-Frankfurt, Center for Advanced Radiomolecular Precision Oncology, 65191 Wiesbaden, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,8,14]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"4396","DOI":"10.1007\/s00259-021-05475-0","article-title":"State-of-the-art of FAPI-PET imaging: A systematic review and meta-analysis","volume":"48","author":"Sollini","year":"2021","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"2844","DOI":"10.1007\/s00259-022-05706-y","article-title":"Clinical summary of fibroblast activation protein inhibitor-based radiopharmaceuticals: Cancer and beyond","volume":"49","author":"Li","year":"2022","journal-title":"Eur. J. Nucl Med. Mol. Imaging"},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Gilardi, L., Air\u00f2 Farulla, L.S., Demirci, E., Clerici, I., Omodeo Sal\u00e8, E., and Ceci, F. (2022). Imaging Cancer-Associated Fibroblasts (CAFs) with FAPi PET. Biomedicines, 10.","DOI":"10.20944\/preprints202201.0327.v1"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1007\/s11864-022-00967-z","article-title":"New PET Radiotracers for the Imaging of Neuroendocrine Neoplasms","volume":"23","author":"Fortunati","year":"2022","journal-title":"Curr. Treat. Options Oncol."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Te Beek, E.T., Burggraaf, J., Teunissen, J.J.M., and Vriens, D. (2022). Clinical pharmacology of radiotheranostics in oncology. Clin. Pharmacol. Ther.","DOI":"10.1002\/cpt.2598"},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Lindner, T., Giesel, F.L., Kratochwil, C., and Serfling, S.E. (2021). Radioligands Targeting Fibroblast Activation Protein (FAP). Cancers, 13.","DOI":"10.3390\/cancers13225744"},{"key":"ref_7","first-page":"757","article-title":"Cancer-associated fibroblasts in colorectal cancer","volume":"24","author":"Pezeshki","year":"2022","journal-title":"Clin. Transl. Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"19441","DOI":"10.1074\/jbc.C500092200","article-title":"Structural and kinetic analysis of the substrate specificity of human fibroblast activation protein alpha","volume":"280","author":"Aertgeerts","year":"2005","journal-title":"J. Biol. Chem."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1007\/s00259-019-04611-1","article-title":"Evaluation of [68Ga]Ga-DATA-TOC for imaging of neuroendocrine tumours: Comparison with [68Ga]Ga-DOTA-NOC PET\/CT","volume":"47","author":"Yadav","year":"2020","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1517\/14728220903103841","article-title":"The road to integrative cancer therapies: Emergence of a tumor-associated fibroblast protease as a potential therapeutic target in cancer","volume":"13","year":"2009","journal-title":"Expert Opin. Ther. Targets"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1007\/s10555-020-09909-3","article-title":"The role of fibroblast activation protein in health and malignancy","volume":"39","author":"Fitzgerald","year":"2020","journal-title":"Cancer Metastasis Rev."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"3203","DOI":"10.3892\/mmr.2015.3197","article-title":"Fibroblast activation protein \u03b1 in tumor microenvironment: Recent progression and implications (review)","volume":"11","author":"Zi","year":"2015","journal-title":"Mol. Med. Rep."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1111\/j.1742-4658.2009.07526.x","article-title":"The dipeptidyl peptidase IV family in cancer and cell biology","volume":"277","author":"Yu","year":"2010","journal-title":"FEBS J."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1002\/prca.201300095","article-title":"Understanding fibroblast activation protein (FAP): Substrates, activities, expression and targeting for cancer therapy","volume":"8","author":"Hamson","year":"2014","journal-title":"Proteom.-Clin. Appl."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1097\/RLU.0000000000004193","article-title":"Uncommon Metastases From Occult Breast Cancer Revealed by 18F-FDG and 68Ga-FAPI PET\/CT","volume":"47","author":"Xu","year":"2022","journal-title":"Clin. Nucl. Med."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1007\/s00259-021-05576-w","article-title":"Positron emission tomography and computed tomography with [68Ga]Ga-fibroblast activation protein inhibitors improves tumor detection and staging in patients with pancreatic cancer","volume":"49","author":"Pang","year":"2022","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1097\/RLU.0000000000003998","article-title":"Differentiation of Reactive Lymph Nodes and Tumor Metastatic Lymph Nodes With 68Ga-FAPI PET\/CT in a Patient With Squamous Cell Lung Cancer","volume":"47","author":"Shang","year":"2022","journal-title":"Clin. Nucl. Med."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"4377","DOI":"10.1007\/s00259-021-05307-1","article-title":"Head-to-head intra-individual comparison of biodistribution and tumor uptake of (68)Ga-FAPI and (18)F-FDG PET\/CT in cancer patients","volume":"48","author":"Giesel","year":"2021","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1097\/RLU.0000000000003637","article-title":"68Ga-FAPI Uptake of Thyroiditis in a Patient With Breast Cancer","volume":"46","author":"Can","year":"2021","journal-title":"Clin. Nucl. Med."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1097\/RLU.0000000000003561","article-title":"Comparison of 68Ga-FAPI and 18F-FDG PET\/CT in the Imaging of Pancreatic Cancer with Liver Metastases","volume":"46","author":"Deng","year":"2021","journal-title":"Clin. Nucl. Med."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"2635","DOI":"10.1007\/s00259-021-05194-6","article-title":"Non-malignant findings of focal (68)Ga-FAPI-04 uptake in pancreas","volume":"48","author":"Zhang","year":"2021","journal-title":"Eur. J. Nucl. Med. Mol. Imaging."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"779","DOI":"10.2967\/jnumed.120.253062","article-title":"Impact of (68)Ga-FAPI PET\/CT Imaging on the Therapeutic Management of Primary and Recurrent Pancreatic Ductal Adenocarcinomas","volume":"62","author":"Naumann","year":"2021","journal-title":"J. Nucl. Med."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"266","DOI":"10.2967\/jnumed.120.244723","article-title":"Fibroblast Activation Protein-Targeted PET\/CT with (68)Ga-FAPI for Imaging IgG4-Related Disease: Comparison to (18)F-FDG PET\/CT","volume":"62","author":"Luo","year":"2021","journal-title":"J. Nucl. Med."},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Roth, K.S., Voltin, C.A., van-Heek, L., Wegen, S., Schomaecker, K., Fischer, T., Marnitz, S., Drzezga, A.E., and Kobe, C. (2022). Dual-tracer PET\/CT protocol with [18F]-FDG and [68Ga]Ga-FAPI-46 for cancer imaging\u2014A proof of concept. J. Nucl. Med.","DOI":"10.2967\/jnumed.122.263835"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1148\/radiol.2021204677","article-title":"Simultaneous FAPI PET\/MRI Targeting the Fibroblast-Activation Protein for Breast Cancer","volume":"302","author":"Backhaus","year":"2022","journal-title":"Radiology"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"127","DOI":"10.2967\/jnumed.121.261925","article-title":"Fibroblast Activation Protein-Specific PET\/CT Imaging in Fibrotic Interstitial Lung Diseases and Lung Cancer: A Translational Exploratory Study","volume":"63","author":"Leitz","year":"2022","journal-title":"J. Nucl. Med."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"797960","DOI":"10.3389\/fonc.2021.797960","article-title":"FAPI PET\/CT in the Diagnosis of Abdominal and Pelvic Tumors","volume":"11","author":"Yang","year":"2021","journal-title":"Front. Oncol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.cpet.2021.03.012","article-title":"The Role of Fibroblast Activation Protein Ligands in Oncologic PET Imaging","volume":"16","author":"Dendl","year":"2021","journal-title":"PET Clin."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1097\/RLU.0000000000004038","article-title":"Pleural Metastasis of Papillary Thyroid Cancer Depicted by 68Ga-FAPI PET\/CT","volume":"47","author":"Chen","year":"2022","journal-title":"Clin. Nucl. Med."},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Fu, L., Huang, S., Wu, H., Dong, Y., Xie, F., Wu, R., Zhou, K., Tang, G., and Zhou, W. (2022). Superiority of [68Ga]Ga-FAPI-04\/[18F]FAPI-42 PET\/CT to [18F]FDG PET\/CT in delineating the primary tumor and peritoneal metastasis in initial gastric cancer. Eur. Radiol., 1\u201310.","DOI":"10.1007\/s00330-022-08743-1"},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Imlimthan, S., Moon, E.S., Rathke, H., Afshar-Oromieh, A., R\u00f6sch, F., Rominger, A., and Gourni, E. (2021). New Frontiers in Cancer Imaging and Therapy Based on Radiolabeled Fibroblast Activation Protein Inhibitors: A Rational Review and Current Progress. Pharmaceuticals, 14.","DOI":"10.3390\/ph14101023"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"3467","DOI":"10.1021\/jm400351a","article-title":"Identification of selective and potent inhibitors of fibroblast activation protein and prolyl oligopeptidase","volume":"56","author":"Poplawski","year":"2013","journal-title":"J. Med. Chem."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"949","DOI":"10.4155\/fmc.10.21","article-title":"Strategies for discovering and derisking covalent, irreversible enzyme inhibitors","volume":"2","author":"Johnson","year":"2010","journal-title":"Future Med. Chem."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"3420","DOI":"10.1158\/1078-0432.CCR-19-2238","article-title":"OMTX705, a Novel FAP-Targeting ADC Demonstrates Activity in Chemotherapy and Pembrolizumab-Resistant Solid Tumor Models","volume":"26","author":"Fabre","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"640566","DOI":"10.3389\/fchem.2021.640566","article-title":"In Vitro and In Situ Activity-Based Labeling of Fibroblast Activation Protein with UAMC1110-Derived Probes","volume":"9","author":"Tanc","year":"2021","journal-title":"Front. Chem."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1021\/acsmedchemlett.9b00191","article-title":"Novel Small Molecule-Derived, Highly Selective Substrates for Fibroblast Activation Protein (FAP)","volume":"10","author":"Vliegen","year":"2019","journal-title":"ACS Med. Chem. Lett."},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Gunderson, A.J., Yamazaki, T., Mccarty, K., Phillips, M., Alice, A., Bambina, S., Zebertavage, L., Friedman, D., Cottam, B., and Newell, P. (2019). Blockade of fibroblast activation protein in combination with radiation treatment in murine models of pancreatic adenocarcinoma. PLoS ONE., 14.","DOI":"10.1371\/journal.pone.0211117"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"3412","DOI":"10.1016\/j.bmcl.2012.03.107","article-title":"Acylated Gly-(2-cyano)pyrrolidines as inhibitors of fibroblast activation protein (FAP) and the issue of FAP\/prolyl oligopeptidase (PREP)-selectivity","volume":"22","author":"Ryabtsova","year":"2012","journal-title":"Bioorganic Med. Chem. Lett."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.2967\/jnumed.118.210435","article-title":"A Tumor-Imaging Method Targeting Cancer-Associated Fibroblasts","volume":"59","author":"Loktev","year":"2018","journal-title":"J. Nucl. Med."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1039\/C4MD00167B","article-title":"Selective inhibitors of fibroblast activation protein (FAP) with a xanthine scaffold","volume":"5","author":"Jansen","year":"2014","journal-title":"MedChemComm"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"801","DOI":"10.2967\/jnumed.119.227967","article-title":"68Ga-FAPI PET\/CT: Tracer Uptake in 28 Different Kinds of Cancer","volume":"60","author":"Kratochwil","year":"2019","journal-title":"J. Nucl. Med."},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"Da Pieve, C., Costa Braga, M., Turton, D.R., Valla, F.A., Cakmak, P., Plate, K.H., and Kramer-Marek, G. (2022). New Fully Automated Preparation of High Apparent Molar Activity (68)Ga-FAPI-46 on a Trasis AiO Platform. Molecules, 27.","DOI":"10.3390\/molecules27030675"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"862","DOI":"10.2967\/jnumed.121.263016","article-title":"Synthesis, preclinical evaluation, and a pilot clinical PET imaging study of (68)Ga-labeled FAPI dimer","volume":"63","author":"Zhao","year":"2021","journal-title":"J. Nucl. Med."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1007\/s00259-021-05638-z","article-title":"[18F]AlF-NOTA-FAPI-04 PET\/CT uptake in metastatic lesions on PET\/CT imaging might distinguish different pathological types of lung cancer","volume":"49","author":"Wei","year":"2022","journal-title":"Eur. J. Nucl. Med. Mol. Imaging."},{"key":"ref_45","doi-asserted-by":"crossref","unstructured":"Hu, K., Li, L., Huang, Y., Ye, S., Zhong, J., Yan, Q., Zhong, Y., Fu, L., Feng, P., and Li, H. (2022). Radiosynthesis and Preclinical Evaluation of Bispecific PSMA\/FAP Heterodimers for Tumor Imaging. Pharmaceuticals, 15.","DOI":"10.3390\/ph15030383"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"2705","DOI":"10.1007\/s00259-022-05757-1","article-title":"18F- or 177Lu-labeled bivalent ligand of fibroblast activation protein with high tumor uptake and retention","volume":"49","author":"Li","year":"2022","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"2761","DOI":"10.1007\/s00259-022-05758-0","article-title":"[18F]AlF-NOTA-FAPI-04: FAP-targeting specificity, biodistribution, and PET\/CT imaging of various cancers","volume":"49","author":"Wei","year":"2022","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/s41181-021-00142-z","article-title":"One-pot and one-step automated radio-synthesis of [18F]AlF-FAPI-74 using a multi purpose synthesizer: A proof-of-concept experiment","volume":"6","author":"Naka","year":"2021","journal-title":"EJNMMI Radiopharm. Chem."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/s41181-021-00144-x","article-title":"(18)F-labeled tracers targeting fibroblast activation protein","volume":"6","author":"Lindner","year":"2021","journal-title":"EJNMMI Radiopharm. Chem."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1016\/j.apsb.2021.09.032","article-title":"Preclinical evaluation and pilot clinical study of [18F]AlF-labeled FAPI-tracer for PET imaging of cancer associated fibroblasts","volume":"12","author":"Hu","year":"2022","journal-title":"Acta Pharm. Sin. B."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"e49","DOI":"10.1097\/RLU.0000000000003863","article-title":"Hepatic Lesion of Mucosa-Associated Lymphoid Tissue Lymphoma Revealed by Al18F-NOTA-FAPI-04 PET\/CT","volume":"47","author":"Kou","year":"2022","journal-title":"Clin. Nucl. Med."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"e570","DOI":"10.1097\/RLU.0000000000003727","article-title":"Al18F-NOTA-FAPI-04 Outperforms 18F-FDG PET\/CT in Identifying the Primary Lesion and Rare Metastases From Gastric Cancer","volume":"46","author":"Kou","year":"2021","journal-title":"Clin. Nucl. Med."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"4259","DOI":"10.1007\/s00259-021-05470-5","article-title":"Clinical translational evaluation of Al(18)F-NOTA-FAPI for fibroblast activation protein-targeted tumour imaging","volume":"48","author":"Wang","year":"2021","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"649148","DOI":"10.3389\/fonc.2021.649148","article-title":"FAPI-04 PET\/CT Using [18F]AlF Labeling Strategy: Automatic Synthesis, Quality Control, and In Vivo Assessment in Patient","volume":"11","author":"Jiang","year":"2021","journal-title":"Front. Oncol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.2967\/jnumed.118.224469","article-title":"Development of Fibroblast Activation Protein-Targeted Radiotracers with Improved Tumor Retention","volume":"60","author":"Loktev","year":"2019","journal-title":"J. Nucl. Med."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/s41181-019-0069-0","article-title":"Targeting of activated fibroblasts for imaging and therapy","volume":"4","author":"Lindner","year":"2019","journal-title":"EJNMMI Radiopharm. Chem."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.2967\/jnumed.118.210443","article-title":"Development of Quinoline-Based Theranostic Ligands for the Targeting of Fibroblast Activation Protein","volume":"59","author":"Lindner","year":"2018","journal-title":"J. Nucl. Med."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1038\/s41573-018-0004-1","article-title":"Turning foes to friends: Targeting cancer-associated fibroblasts","volume":"18","author":"Chen","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"2833","DOI":"10.1007\/s00259-021-05646-z","article-title":"[18F]FAPI-42 PET imaging in cancer patients: Optimal acquisition time, biodistribution, and comparison with [68Ga]Ga-FAPI-04","volume":"49","author":"Hu","year":"2022","journal-title":"Eur. J Nucl. Med. Mol. Imaging"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"563","DOI":"10.2967\/jnumed.119.233122","article-title":"Theranostics Targeting Fibroblast Activation Protein in the Tumor Stroma: (64)Cu- and (225)Ac-Labeled FAPI-04 in Pancreatic Cancer Xenograft Mouse Models","volume":"61","author":"Watabe","year":"2020","journal-title":"J. Nucl. Med."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"3011","DOI":"10.1007\/s00259-021-05273-8","article-title":"[153Sm]Samarium-labeled FAPI-46 radioligand therapy in a patient with lung metastases of a sarcoma","volume":"48","author":"Kratochwil","year":"2021","journal-title":"Eur. J. Nucl. Med. Mol. Imaging."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1097\/RLU.0000000000003842","article-title":"Two Tumors, One Target: Preliminary Experience With 90Y-FAPI Therapy in a Patient With Metastasized Breast and Colorectal Cancer","volume":"46","author":"Rathke","year":"2021","journal-title":"Clin. Nucl. Med."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"e243","DOI":"10.1097\/RLU.0000000000004021","article-title":"177Lu-FAPI Therapy in a Patient With End-Stage Metastatic Pancreatic Adenocarcinoma","volume":"47","author":"Kaghazchi","year":"2022","journal-title":"Clin. Nucl. Med."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"952","DOI":"10.2967\/jnumed.121.262533","article-title":"Albumin Binder-Conjugated Fibroblast Activation Protein Inhibitor Radiopharmaceuticals for Cancer Therapy","volume":"63","author":"Xu","year":"2021","journal-title":"J. Nucl. Med."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1007\/s00259-021-05554-2","article-title":"Fibroblast activation protein targeted therapy using [177Lu]FAPI-46 compared with [225Ac]FAPI-46 in a pancreatic cancer model","volume":"49","author":"Liu","year":"2022","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1097\/RLU.0000000000003667","article-title":"Safety of Fibroblast Activation Protein-Targeted Radionuclide Therapy by a Low-Dose Dosimetric Approach Using 177Lu-FAPI04","volume":"46","author":"Kuyumcu","year":"2021","journal-title":"Clin. Nucl. Med."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"e523","DOI":"10.1097\/RLU.0000000000003810","article-title":"Feasibility and Therapeutic Potential of 177Lu-Fibroblast Activation Protein Inhibitor-46 for Patients With Relapsed or Refractory Cancers: A Preliminary Study","volume":"46","author":"Assadi","year":"2021","journal-title":"Clin. Nucl. Med."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"415","DOI":"10.2967\/jnumed.120.259192","article-title":"Feasibility, Biodistribution, and Preliminary Dosimetry in Peptide-Targeted Radionuclide Therapy of Diverse Adenocarcinomas Using (177)Lu-FAP-2286: First-in-Humans Results","volume":"63","author":"Baum","year":"2022","journal-title":"J. Nucl. Med."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"49586","DOI":"10.1039\/C7RA09076E","article-title":"Comparison of macrocyclic and acyclic chelators for gallium-68 radiolabelling","volume":"7","author":"Tsionou","year":"2017","journal-title":"RSC Adv."},{"key":"ref_70","doi-asserted-by":"crossref","unstructured":"Fersing, C., Masurier, N., Rubira, L., Deshayes, E., and Lisowski, V. (2022). AAZTA-Derived Chelators for the Design of Innovative Radiopharmaceuticals with Theranostic Applications. Pharmaceuticals, 15.","DOI":"10.3390\/ph15020234"},{"key":"ref_71","doi-asserted-by":"crossref","unstructured":"Tornesello, A.L., Buonaguro, L., Tornesello, M.L., and Buonaguro, F.M. (2017). New Insights in the Design of Bioactive Peptides and Chelating Agents for Imaging and Therapy in Oncology. Molecules, 22.","DOI":"10.3390\/molecules22081282"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"7588","DOI":"10.1021\/ic0489692","article-title":"[Gd-AAZTA]-: A new structural entry for an improved generation of MRI contrast agents","volume":"43","author":"Aime","year":"2004","journal-title":"Inorg. Chem."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1039\/C2CC37544C","article-title":"Structure and stability of hexadentate complexes of ligands based on AAZTA for efficient PET labelling with gallium-68","volume":"49","author":"Waldron","year":"2013","journal-title":"Chem. Commun."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s41181-020-00102-z","article-title":"Targeting fibroblast activation protein (FAP): Next generation PET radiotracers using squaramide coupled bifunctional DOTA and DATA(5m) chelators","volume":"5","author":"Moon","year":"2020","journal-title":"EJNMMI Radiopharm. Chem."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"112872","DOI":"10.1016\/j.ejmech.2020.112872","article-title":"Squaric acid analogues in medicinal chemistry","volume":"209","author":"Urban","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"8220","DOI":"10.1039\/c3cs60153f","article-title":"Be squared: Expanding the horizon of squaric acid-mediated conjugations","volume":"42","author":"Wurm","year":"2013","journal-title":"Chem. Soc. Rev."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1002\/cmdc.201900559","article-title":"Synthesis, Labeling and Preclinical Evaluation of a Squaric Acid Containing PSMA Inhibitor Labeled with (68) Ga: A Comparison with PSMA-11 and PSMA-617","volume":"15","author":"Greifenstein","year":"2020","journal-title":"ChemMedChem"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"108867","DOI":"10.1016\/j.apradiso.2019.108867","article-title":"Synthesis and labeling of a squaric acid containing PSMA-inhibitor coupled to AAZTA5 for versatile labeling with 44Sc, 64Cu, 68Ga and 177Lu","volume":"156","author":"Greifenstein","year":"2020","journal-title":"Appl. Radiat. Isot."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"3553","DOI":"10.1002\/cber.19701031119","article-title":"Kondensationsprodukte der Quadrats\u00e4ure mit prim\u00e4ren und sekund\u00e4ren Aminen, II","volume":"103","author":"Gauger","year":"1970","journal-title":"Chem. Berichte"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1007\/s00259-020-04990-w","article-title":"A theranostic approach of [68Ga]Ga-DOTA.SA.FAPi PET\/CT-guided [177Lu]Lu-DOTA.SA.FAPi radionuclide therapy in an end-stage breast cancer patient: New frontier in targeted radionuclide therapy","volume":"48","author":"Ballal","year":"2021","journal-title":"Eur. J. Nucl. Med. Mol. Imaging."},{"key":"ref_81","doi-asserted-by":"crossref","unstructured":"Ballal, S., Yadav, M.P., Moon, E.S., Kramer, V.S., Roesch, F., Kumari, S., and Bal, C. (2021). First-In-Human Results on the Biodistribution, Pharmacokinetics, and Dosimetry of [177Lu]Lu-DOTA.SA.FAPi and [177Lu]Lu-DOTAGA.(SA.FAPi)(2). Pharmaceuticals, 14.","DOI":"10.21203\/rs.3.rs-786088\/v1"},{"key":"ref_82","first-page":"65","article-title":"Novel Fibroblast Activation Protein Inhibitor-Based Targeted Theranostics for Radioiodine-Refractory Differentiated Thyroid Cancer Patients: A Pilot Study","volume":"32","author":"Ballal","year":"2022","journal-title":"Thyroid"},{"key":"ref_83","first-page":"476","article-title":"Fibroblast Activation Protein (FAP) targeting homodimeric FAP inhibitor radiotheranostics: A step to improve tumor uptake and retention time","volume":"11","author":"Moon","year":"2021","journal-title":"Am. J. Nucl. Med. Mol. Imaging"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1055\/a-1521-8604","article-title":"Fibroblast activation protein inhibitor (FAPi) positive tumour fraction on PET\/CT correlates with Ki-67 in liver metastases of neuroendocrine tumours","volume":"60","author":"Kreppel","year":"2021","journal-title":"Nuklearmedizin"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1055\/a-1164-5667","article-title":"[68Ga]Ga-DATA5m.SA.FAPi PET\/CT: Specific Tracer-uptake in Focal Nodular Hyperplasia and potential Role in Liver Tumor Imaging","volume":"59","author":"Kreppel","year":"2020","journal-title":"Nuklearmedizin"},{"key":"ref_86","unstructured":"Glatting, F.M., Hoppner, J., Liew, D.P., van Genabith, A., Spektor, A.M., Steinbach, L., Hubert, A., Kratochwil, C., Giesel, F.L., and Dendl, K. (J. Nucl. Med., 2022). Repetitive early FAPI-PET acquisition comparing FAPI-02, FAPI-46 and FAPI-74: Methodological and diagnostic implications for malignant, inflammatory and degenerative lesions, J. Nucl. Med., online ahead of print."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"386","DOI":"10.2967\/jnumed.118.215913","article-title":"68Ga-FAPI PET\/CT: Biodistribution and Preliminary Dosimetry Estimate of 2 DOTA-Containing FAP-Targeting Agents in Patients with Various Cancers","volume":"60","author":"Giesel","year":"2019","journal-title":"J. Nucl. Med."}],"container-title":["Pharmaceuticals"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1424-8247\/15\/8\/1000\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T00:08:36Z","timestamp":1760141316000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1424-8247\/15\/8\/1000"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,14]]},"references-count":87,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2022,8]]}},"alternative-id":["ph15081000"],"URL":"https:\/\/doi.org\/10.3390\/ph15081000","relation":{},"ISSN":["1424-8247"],"issn-type":[{"value":"1424-8247","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,14]]}}}